Literature DB >> 15652948

Angiotensin II type 1 receptor activation increases microvascular permeability via a calcium dependent process.

Christopher R Newton1, Brian Curran, Gregory P Victorino.   

Abstract

BACKGROUND: Elevated serum angiotensin II (Ang II) has been implicated in the endothelial barrier dysfunction associated with shock. We hypothesized that the increase in microvascular permeability seen with activation of the type 1 (AT1) receptor is a calcium dependent process.
MATERIALS AND METHODS: Microvascular hydraulic permeability (Lp) was measured in rat mesenteric venules using the Landis micro-occlusion model. A 100 mm KCl (HK) solution was used to negate the electrochemical potential of calcium influx, and measures of Lp were obtained before and after 20 ng/ml Ang II plus HK solution (n = 5). Intracellular calcium dependence on AT1 activation was evaluated two ways: 1) Lp changes were measured in response to 10 microm of the type 1 receptor agonist [SAR] [1]-angiotensin II in HK solution (n = 6), and 2) Lp changes were measured in response to 25 microg/ml of the type 2 (AT2) receptor blocker PD-123319 (PD) plus 20 ng/ml Ang II in HK solution (n = 6).
RESULTS: As expected, HK perfusion (P < 0.08) and Ang II plus HK solution (P < 0.42) did not affect Lp. Although perfusion of [SAR] [1]-angiotensin II in HK solution (P < 0.001) and PD plus Ang II in HK solution (P < 0.003) both significantly increased Lp, the magnitude of this response was less than that observed with Ang II alone.
CONCLUSIONS: Abrogation of intracellular calcium influx during AT1 activation blunted the known Ang II induced increase in microvascular permeability. Although the effect observed during AT1 activation was blunted by the HK solution, a significant elevation of Lp was still observed. This suggests that Ang II activation of the AT1 receptor increases microvascular permeability primarily, but not exclusively, via modulation of endothelial intracellular calcium ion levels.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15652948     DOI: 10.1016/j.jss.2004.07.020

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  6 in total

1.  A novel role for calpain in the endothelial dysfunction induced by activation of angiotensin II type 1 receptor signaling.

Authors:  Rosario Scalia; Yulan Gong; Brett Berzins; Brin Freund; Danielle Feather; Gavin Landesberg; Gourav Mishra
Journal:  Circ Res       Date:  2011-03-17       Impact factor: 17.367

2.  Endothelial dysfunction induced by antibodies against angiotensin AT1 receptor in immunized rats.

Authors:  Su-li Zhang; Yun-hui Du; Jin Wang; Li-hong Yang; Xiao-li Yang; Rong-hua Zheng; Ye Wu; Ke Wang; Ming-sheng Zhang; Hui-rong Liu
Journal:  Acta Pharmacol Sin       Date:  2010-09-13       Impact factor: 6.150

3.  Orthostatic Challenge Shifts the Hemostatic System of Patients Recovered from Stroke toward Hypercoagulability.

Authors:  Gerhard Cvirn; Markus Kneihsl; Christine Rossmann; Margret Paar; Thomas Gattringer; Axel Schlagenhauf; Bettina Leschnik; Martin Koestenberger; Erwin Tafeit; Gilbert Reibnegger; Irhad Trozic; Andreas Rössler; Franz Fazekas; Nandu Goswami
Journal:  Front Physiol       Date:  2017-02-07       Impact factor: 4.566

4.  Role and mechanism of AT1-AA in the pathogenesis of HELLP syndrome.

Authors:  Shurui Bu; Yuxian Wang; Shuqing Sun; Yanqian Zheng; Zhu Jin; Jianming Zhi
Journal:  Sci Rep       Date:  2018-01-10       Impact factor: 4.379

5.  Implications of Plasma Renin Activity and Plasma Aldosterone Concentration in Critically Ill Patients with Septic Shock.

Authors:  Kyung Soo Chung; Joo Han Song; Won Jai Jung; Young Sam Kim; Se Kyu Kim; Joon Chang; Moo Suk Park
Journal:  Korean J Crit Care Med       Date:  2017-05-31

6.  Soluble RAGE attenuates AngII-induced endothelial hyperpermeability by disrupting HMGB1-mediated crosstalk between AT1R and RAGE.

Authors:  Jisu Jeong; Jiye Lee; Juyeon Lim; Soyoung Cho; Soyoung An; Myungeun Lee; Nara Yoon; Miran Seo; Soyeon Lim; Sungha Park
Journal:  Exp Mol Med       Date:  2019-09-27       Impact factor: 8.718

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.